Compare Innodata Inc (INOD) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innodata Inc vs Novartis AG — how do they compare? Innodata Inc trades at $62.73 (market cap $2.05B), while Novartis AG trades at $152.84 (market cap $295.37B). The key difference: Novartis AG is far larger — about 144.1× Innodata Inc's market cap, and Novartis AG pays a 3.07% dividend while Innodata Inc pays none. Which is the better fit depends on your goals.
| INOD | NVS | |
|---|---|---|
Market Cap | $2.05B | $295.37B |
Sector | Technology | Health |
52-Week High | $121.50 | $168.62 |
52-Week Low | $34.45 | $119.31 |
Enterprise Value | $1.80B | $336.69B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INOD trades at $61.40, down 1.33% today, but maintains a bullish technical signal with oscillators supporting upside momentum. The company reported strong Q2 2026 results, beating EPS estimates with $0.41 versus $0.21 expected, driven by 58% revenue growth and AI-driven demand expansion. Valuation ratios remain elevated with a P/E of 48.62, reflecting high growth expectations.
Outlook is positive given consistent earnings beats and AI sector tailwinds, but risks include premium valuation sensitivity and customer concentration. Analyst consensus is bullish with a $130 price target, suggesting significant upside potential if execution continues.
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
